Key Takeaways
- Over 10 years, only 2 of 3,477 men treated with focal therapy died of prostate cancer, a cancer-specific survival near 99.9% that the researchers say matches surgery and radiotherapy.
- Urinary and sexual side effects ran at under half the rate seen with whole-gland treatment, the trade-off patients care most about.
- The catch is access: about 1,000 men a year get focal therapy on the NHS out of an estimated 15,000 who could qualify.
Same cancer control, less collateral damage
The hard question in early prostate cancer has never really been survival. Most men do well. The question is what the treatment costs you: surgery and radiotherapy for the whole gland can leave lasting incontinence and erectile dysfunction, because they hit healthy tissue along with the tumor. Focal therapy tries to sidestep that by treating only the cancerous zone and leaving the rest of the prostate intact.
A new study is the strongest evidence yet that the trade actually works. A team at Imperial College London, working across 14 UK hospitals, followed 3,477 men treated with focal therapy, either high-intensity focused ultrasound or cryotherapy, between 2004 and 2024. The results land on both counts that matter.
What the numbers show
| Measure | Result |
|---|---|
| Men treated | 3,477 across 14 UK hospitals |
| Deaths from prostate cancer at 10 years | 2 (about 0.1%) |
| Cancer spread beyond the prostate | About 3% |
| Urinary / sexual side effects | Less than half the whole-gland rate |
Two cancer deaths in over three thousand men is a cancer-specific survival of roughly 99.9% at 10 years. Prof. Hashim Ahmed, chair of urology at Imperial and co-senior author of the study in European Urology, called it the largest and longest-running evidence that focal therapy delivers strong long-term cancer control across a broad range of patients. Crucially, control matched surgery and radiation, so the lower side-effect burden does not come at the price of letting the cancer win.
The access problem
Here is where the story turns frustrating. A treatment with survival on par with surgery and a fraction of the harm should be easy to expand. It is not. Only about 10 NHS centres in England offer focal therapy, and none in Wales, Scotland, or Northern Ireland, so where you live largely decides whether you can get it.
The gap in raw numbers is stark: roughly 1,000 men a year actually receive it, against an estimated 15,000 who could be eligible. NICE still classifies focal therapy as non-routine, meaning the NHS is not required to offer it, and Prostate Cancer UK has pushed for that guidance to be reviewed on the strength of the side-effect data. There is also a national MRI-screening trial in the works that would fold focal therapy in for screen-detected cases, tying a low-harm treatment to a possible future screening program.
For now the science is well ahead of the plumbing. The 10-year data make a strong case that, for the right tumors in experienced hands, you can treat prostate cancer hard without wrecking quality of life. Whether most eligible men can get that option is a question of capacity and policy, not evidence.
Sources:
- BBC News, “Prostate cancer focal therapy ‘as effective as surgery’ with fewer side effects”
- Imperial College Healthcare NHS Trust, “New study shows focal therapy treats prostate cancer”
- European Urology (Ahmed et al., 10-year focal therapy outcomes)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.